Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Dry Eye Syndrome (DES) is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. With a rapidly accelerating worldwide prevalence and the limited treatment options available, there is a growing pressure for new therapies and curative treatment for DES patients. Significant efforts are being made to develop a new treatment for DES, as current pharmacologic management is known to only provide temporary symptomatic relief.
GlobalData estimates the 2016 sales for DES at approximately $2.2B across the 8MM covered in this report.
The DES pipeline activity comprises 10 active Phase III (or Phase II/III) pipeline agents with novel mechanisms of action as well as cyclosporines with improved clinical profiles. Additionally, six of these late-stage pipeline drugs are expected to be first-in-class therapies. The most notable pipeline drugs include RegeneRx’s thymosin beta-4 product RGN-259, Aldeyra’s reproxalap which acts as an “aldehyde trap”, and Sylentis’ TRPV1 inhibitor tivanisiran. Other late-phase novel drugs include Mitotech’s mitochondrial antioxidant product visomitin, Kala Pharmaceuticals’ corticosteroid KPI-121, and Novartis’ and Dompe’s recombinant human lubricin protein ECF-843. GlobalData expects these new drugs will expand the DES treatment options and contribute to overall market growth. Nevertheless, considerable opportunities remain within this severely underserved DES market.
Key Questions Answered
What are the key unmet needs clinically and in research? What do KOLs identify as the key unmet needs? Will the products in the DES pipeline fill these unmet needs?
When are the pipeline products expected to launch? What are the key features of the products in the pipeline?
What are the threats for drugs currently on the market? How will the new pipeline products be incorporated into the current treatment algorithm?
What are the key hurdles for manufacturers entering the DES market?
Scope
Overview of DES: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
Annualized DES market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild DES, moderate DES, and severe DES), forecast from 2016 to 2026.
Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DES therapeutics market
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DES therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.
Analysis of the current and future market competition in the global DES therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global DES therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DES therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Alcon
Aldeyra
Allergan
Altacor
Apotex
Argentum Pharmaceuticals
Aspire
Auven Therapeutics
Bausch & Lomb
Chongqing Santen Kerui Pharmaceutical
Dompe
Famy Care Limited
G-TreeBNT
Greenstone
Intrexon Corporation
Kaken
Kala Pharmaceuticals
Kyorin
Laboratoires Thea
Lee’s Pharmaceutical
Lubris Biopharma
Magenta
MC2 Therapeutics
Mitotech
Mylan
Moorfield Pharmaceuticals
Nippon
Nissiin
Novaliq
Novartis
Otsuka
Parion Sciences
Pfizer
Pfizer’s InnoPharma
PharmaMar
Rayner
RegeneRx
Santen
Scope Ophthalmics
Seikagaku
Senju
Shire
Sun Pharmaceutical
Sylentis
Thea
Toa
Twi Pharmaceuticals
United Laboratories
Ursapharm
Wakamoto
Wockhardt
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.